Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

达拉图穆马 来那度胺 医学 地塞米松 多发性骨髓瘤 肿瘤科 内科学 人口 自体干细胞移植 外科 环境卫生
作者
Thierry T.F. Facon,Shaji Kunnathu Kumar,Torben Plesner,Robert Zygmunt Orlowski,Philippe Moreau,Nizar Jacques Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael E O'Dwyer,Aurore Perrot,Christopher Paul Venner,Katja Christina Weisel,Joseph Ronald Mace,Noopur S Raje,Michel Attal,Mourad Tiab,Margaret Macro
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:380 (22): 2104-2115 被引量:1017
标识
DOI:10.1056/nejmoa1817249
摘要

BACKGROUNDLenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. METHODSWe randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group).Treatment was to continue until the occurrence of disease progression or unacceptable side effects.The primary end point was progression-free survival. RESULTSAt a median follow-up of 28.0 months, disease progression or death had occurred in 240 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 369 patients [38.8%] in the control group).The estimated percentage of patients who were alive without disease progression at 30 months was 70.6% (95% confidence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 49.5 to 61.3) in the control group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.43 to 0.73; P<0.001).The percentage of patients with a complete response or better was 47.6% in the daratumumab group and 24.9% in the control group (P<0.001).A total of 24.2% of the patients in the daratumumab group, as compared with 7.3% of the patients in the control group, had results below the threshold for minimal residual disease (1 tumor cell per 10 5 white cells) (P<0.001).The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%),lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). CONCLUSIONSAmong patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone.A higher incidence of neutropenia and pneumonia was observed in the daratumumab group.(Funded by Janssen Research and Development; MAIA ClinicalTrials.govnumber, NCT02252172.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李健的粉丝团团长的应助被buqi采纳,获得50
1秒前
2秒前
kinghao发布了新的文献求助10
3秒前
陈烨完成签到,获得积分20
4秒前
Ujana发布了新的文献求助30
4秒前
完美世界的应助被研通小弟采纳,获得10
5秒前
5秒前
6秒前
8秒前
香蕉觅云的应助被buqi采纳,获得50
8秒前
MichaelFrancis完成签到,获得积分10
8秒前
田様的应助被kinghao采纳,获得10
9秒前
苏芳勤发布了新的文献求助10
9秒前
科研通AI6.4的应助被牧百川采纳,获得10
10秒前
hanhan完成签到,获得积分10
10秒前
10秒前
邓六一发布了新的文献求助10
10秒前
吃吃吃完成签到,获得积分10
11秒前
共享精神的应助被感性的太阳采纳,获得10
11秒前
丘比特的应助被lllll采纳,获得10
11秒前
startt发布了新的文献求助10
12秒前
nhzz2023发布了新的文献求助10
12秒前
zhang完成签到,获得积分10
13秒前
kinghao完成签到,获得积分10
14秒前
17秒前
17秒前
17秒前
希望天下0贩的0的应助被wh采纳,获得10
17秒前
19秒前
20秒前
SciGPT的应助被6366336采纳,获得10
20秒前
深情安青的应助被清风白采纳,获得10
20秒前
20秒前
自建完成签到,获得积分10
21秒前
21秒前
22秒前
22秒前
22秒前
23秒前
风中的糖豆完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496